MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Earnings for MiNK Therapeutics, Inc. (INKT)
Earnings in 2023 (TTM): $-22,457,859
According to MiNK Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-22,457,859. The earnings displayed on this page is the company's Pretax Income.
Earnings history of MiNK Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-22,457,859 | $-22,457,859 |
| 2022 | $-27,991,212 | $-24,779,823 |
| 2021 | $-30,212,770 | $-23,114,009 |
| 2020 | $-16,238,898 | $-15,678,517 |
| 2019 | $-23,802,182 | $-25,914,285 |